$6.1623
-0.3077[-4.76%]
At close: Apr 25
$6.1623
0[0.00%]
After Hours: 6:37PM EDT
C4 Therapeutics
(NASDAQ:CCCC)C4 Therapeutics Stock (NASDAQ:CCCC), Analyst Ratings, Price Targets, Predictions
C4 Therapeutics Inc has a consensus price target of $19, established from looking at the 31 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, Stifel, and JP Morgan on February 26, 2024, February 23, 2024, and January 29, 2024. With an average price target of $9 between Morgan Stanley, Stifel, and JP Morgan, there's an implied 46.05% upside for C4 Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Stifel
JP Morgan
BMO Capital
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for C4 Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/26/2024 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 29.82% | Morgan Stanley | Terence Flynn | $1 → $8 | Maintains | Equal-Weight | Get Alert |
| 02/23/2024 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 110.96% | Stifel | Bradley Canino | $12 → $13 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2024 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -2.63% | JP Morgan | Eric Joseph | → $6 | Upgrade | Underweight → Neutral | Get Alert |
| 12/13/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 94.73% | Stifel | Bradley Canino | $2 → $12 | Upgrade | Hold → Buy | Get Alert |
| 11/06/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -83.77% | Morgan Stanley | Terence Flynn | $3 → $1 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/03/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 159.64% | BMO Capital | Etzer Darout | $18 → $16 | Maintains | Outperform | Get Alert |
| 11/02/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 13.59% | HC Wainwright & Co. | Andrew Fein | $17 → $7 | Maintains | Buy | Get Alert |
| 10/09/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -67.54% | B of A Securities | Chi Fong | $5 → $2 | Maintains | Neutral | Get Alert |
| 08/09/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 175.87% | HC Wainwright & Co. | Andrew Fein | $25 → $17 | Maintains | Buy | Get Alert |
| 05/30/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 62.28% | Evercore ISI Group | Gavin Clark-Gartner | $20 → $10 | Maintains | Outperform | Get Alert |
| 05/12/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -51.32% | Morgan Stanley | Terence Flynn | $5 → $3 | Maintains | Underweight | Get Alert |
| 05/08/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 305.69% | HC Wainwright & Co. | Andrew Fein | $35 → $25 | Maintains | Buy | Get Alert |
| 03/28/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -18.86% | B of A Securities | Chi Fong | $11 → $5 | Maintains | Neutral | Get Alert |
| 02/27/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -18.86% | Morgan Stanley | Terence Flynn | $6 → $5 | Maintains | Underweight | Get Alert |
| 02/24/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 467.97% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | -18.86% | JP Morgan | Eric Joseph | $15 → $5 | Downgrade | Neutral → Underweight | Get Alert |
| 01/03/2023 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 46.05% | Wells Fargo | Derek Archila | $11 → $9 | Maintains | Equal-Weight | Get Alert |
| 11/08/2022 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 78.5% | Wells Fargo | Derek Archila | $12 → $11 | Maintains | Equal-Weight | Get Alert |
| 11/04/2022 | CCCC | Buy Now | C4 Therapeutics | $6.16 | 143.42% | JP Morgan | Eric Joseph | $22 → $15 | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for C4 Therapeutics (CCCC)?
The latest price target for C4 Therapeutics (NASDAQ: CCCC) was reported by Morgan Stanley on February 26, 2024. The analyst firm set a price target for $8.00 expecting CCCC to rise to within 12 months (a possible 29.82% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for C4 Therapeutics (CCCC)?
The latest analyst rating for C4 Therapeutics (NASDAQ: CCCC) was provided by Morgan Stanley, and C4 Therapeutics maintained their equal-weight rating.
When was the last upgrade for C4 Therapeutics (CCCC)?
The last upgrade for C4 Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $6. JP Morgan previously had an underweight for C4 Therapeutics Inc.
When was the last downgrade for C4 Therapeutics (CCCC)?
The last downgrade for C4 Therapeutics Inc happened on February 24, 2023 when JP Morgan changed their price target from $15 to $5 for C4 Therapeutics Inc.
When is the next analyst rating going to be posted or updated for C4 Therapeutics (CCCC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.
Is the Analyst Rating C4 Therapeutics (CCCC) correct?
While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a maintained with a price target of $1.00 to $8.00. The current price C4 Therapeutics (CCCC) is trading at is $6.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.